Novel Agents in the Treatment of Lung Cancer: Assessing Opportunities for Combination Therapy
Fifth Cambridge Conference - October 2007
This program was based on a conference of multidisciplinary leaders in lung cancer research and clinical care. The focus of the program was to review new data, assess what is known, discuss opportunities and issues for developing novel agents alone and in combination, identify research priorities, and highlight was is important and promising for health care professionals in the community setting. The program developed content for a peer reviewed educational journal publication for medical oncologists and other health care professionals who wish to expand their understanding of new approaches to assessing, treating, and counseling lung cancer patients.
This program was directed by Thomas J. Lynch, Jr., MD , Chief, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center.
Educational Objectives
1) List the principal drug classes that are currently most clinically advanced for the treatment of lung cancer; 2) discuss the key clinical data or clinical status for each principal class of agents; and 3) discuss the rationale for and against combination therapy in lung cancer.
Educational Grant Support
This program is supported by educational grants provided by: Genentech, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Pfizer, Inc., Bayer Healthcare Pharmaceuticals and Onyx, Inc., Boehringer Ingelheim and EMD Serono
Sponsorship
CME sponsorship and program management are provided by InforMEDical.
The conference proceedings were published as a peer-reviewed CME supplement to the Journal of Thoracic Oncology, Vol 3, No 6, Supplement 2, pp S107-S112, June 2008.
The CME activity based on the publication summary is effective June 2008 through June 2009.
Journal Website
(subscription may be required to access full journal supplement)
